Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies

Carol O. Tacket, Genevieve Losonsky, David N. Taylor, Louis S. Baron, Dennis Kopecko, Stanley Cryz, Myron M. Levine

Research output: Contribution to journalArticle

Abstract

New typhoid vaccines have been sought to replace the reactogenic parenteral whole cell vaccines. Both Ty21a, a live oral attenuated Vi-negative Salmonella typhi vaccine strain, and parenteral Vi polysaccharide vaccine are safe and efficacious in field trials. To achieve potentially greater protective efficacy, a derivative of Ty21a that expresses Vi polysaccharide was prepared and its safety and immunogenicity assessed in 27 adult volunteers. The volunteers received either one dose of 5 x 105, 5 x 107, or 5 x 109 cfu or three doses of 5 x 109 cfu of lyophilized vaccine and were observed for adverse effects on a research isolation ward. The vaccine was well tolerated; however, at the highest dose, 13% of volunteers had mild diarrhea. Serial blood cultures were negative for the vaccine strain. Vaccine was shed in the stool of most volunteers at the higher doses for 1-4 days. No serum antibodies to Vi, circulating cells secreting antibody to Vi, or jejunal fluid antibodies to Vi were detected in any volunteer.

Original languageEnglish (US)
Pages (from-to)901-904
Number of pages4
JournalJournal of Infectious Diseases
Volume163
Issue number4
StatePublished - Apr 1991
Externally publishedYes

Fingerprint

Salmonella typhi
Vaccines
Volunteers
Polysaccharides
Salmonella Vaccines
Typhoid-Paratyphoid Vaccines
Antibody-Producing Cells
Antibodies
Diarrhea
Safety
Serum
Research

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Tacket, C. O., Losonsky, G., Taylor, D. N., Baron, L. S., Kopecko, D., Cryz, S., & Levine, M. M. (1991). Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies. Journal of Infectious Diseases, 163(4), 901-904.

Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies. / Tacket, Carol O.; Losonsky, Genevieve; Taylor, David N.; Baron, Louis S.; Kopecko, Dennis; Cryz, Stanley; Levine, Myron M.

In: Journal of Infectious Diseases, Vol. 163, No. 4, 04.1991, p. 901-904.

Research output: Contribution to journalArticle

Tacket, CO, Losonsky, G, Taylor, DN, Baron, LS, Kopecko, D, Cryz, S & Levine, MM 1991, 'Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies', Journal of Infectious Diseases, vol. 163, no. 4, pp. 901-904.
Tacket, Carol O. ; Losonsky, Genevieve ; Taylor, David N. ; Baron, Louis S. ; Kopecko, Dennis ; Cryz, Stanley ; Levine, Myron M. / Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies. In: Journal of Infectious Diseases. 1991 ; Vol. 163, No. 4. pp. 901-904.
@article{6adf95f6c9f04a30a3e474a80af0548f,
title = "Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies",
abstract = "New typhoid vaccines have been sought to replace the reactogenic parenteral whole cell vaccines. Both Ty21a, a live oral attenuated Vi-negative Salmonella typhi vaccine strain, and parenteral Vi polysaccharide vaccine are safe and efficacious in field trials. To achieve potentially greater protective efficacy, a derivative of Ty21a that expresses Vi polysaccharide was prepared and its safety and immunogenicity assessed in 27 adult volunteers. The volunteers received either one dose of 5 x 105, 5 x 107, or 5 x 109 cfu or three doses of 5 x 109 cfu of lyophilized vaccine and were observed for adverse effects on a research isolation ward. The vaccine was well tolerated; however, at the highest dose, 13{\%} of volunteers had mild diarrhea. Serial blood cultures were negative for the vaccine strain. Vaccine was shed in the stool of most volunteers at the higher doses for 1-4 days. No serum antibodies to Vi, circulating cells secreting antibody to Vi, or jejunal fluid antibodies to Vi were detected in any volunteer.",
author = "Tacket, {Carol O.} and Genevieve Losonsky and Taylor, {David N.} and Baron, {Louis S.} and Dennis Kopecko and Stanley Cryz and Levine, {Myron M.}",
year = "1991",
month = "4",
language = "English (US)",
volume = "163",
pages = "901--904",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies

AU - Tacket, Carol O.

AU - Losonsky, Genevieve

AU - Taylor, David N.

AU - Baron, Louis S.

AU - Kopecko, Dennis

AU - Cryz, Stanley

AU - Levine, Myron M.

PY - 1991/4

Y1 - 1991/4

N2 - New typhoid vaccines have been sought to replace the reactogenic parenteral whole cell vaccines. Both Ty21a, a live oral attenuated Vi-negative Salmonella typhi vaccine strain, and parenteral Vi polysaccharide vaccine are safe and efficacious in field trials. To achieve potentially greater protective efficacy, a derivative of Ty21a that expresses Vi polysaccharide was prepared and its safety and immunogenicity assessed in 27 adult volunteers. The volunteers received either one dose of 5 x 105, 5 x 107, or 5 x 109 cfu or three doses of 5 x 109 cfu of lyophilized vaccine and were observed for adverse effects on a research isolation ward. The vaccine was well tolerated; however, at the highest dose, 13% of volunteers had mild diarrhea. Serial blood cultures were negative for the vaccine strain. Vaccine was shed in the stool of most volunteers at the higher doses for 1-4 days. No serum antibodies to Vi, circulating cells secreting antibody to Vi, or jejunal fluid antibodies to Vi were detected in any volunteer.

AB - New typhoid vaccines have been sought to replace the reactogenic parenteral whole cell vaccines. Both Ty21a, a live oral attenuated Vi-negative Salmonella typhi vaccine strain, and parenteral Vi polysaccharide vaccine are safe and efficacious in field trials. To achieve potentially greater protective efficacy, a derivative of Ty21a that expresses Vi polysaccharide was prepared and its safety and immunogenicity assessed in 27 adult volunteers. The volunteers received either one dose of 5 x 105, 5 x 107, or 5 x 109 cfu or three doses of 5 x 109 cfu of lyophilized vaccine and were observed for adverse effects on a research isolation ward. The vaccine was well tolerated; however, at the highest dose, 13% of volunteers had mild diarrhea. Serial blood cultures were negative for the vaccine strain. Vaccine was shed in the stool of most volunteers at the higher doses for 1-4 days. No serum antibodies to Vi, circulating cells secreting antibody to Vi, or jejunal fluid antibodies to Vi were detected in any volunteer.

UR - http://www.scopus.com/inward/record.url?scp=0025908003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025908003&partnerID=8YFLogxK

M3 - Article

C2 - 2010645

AN - SCOPUS:0025908003

VL - 163

SP - 901

EP - 904

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -